Glucose homeostasis and insulin secretion during chronic treatment with cyclosporin in nondiabetic humans.
Cyclosporin or placebo was administered in a randomized, double-blind fashion to 13 patients with multiple sclerosis for 1 yr to determine whether cyclosporin adversely affects glucose homeostasis or beta-cell function. No significant differences were observed in fasting glucose, fasting insulin, intravenous glucose tolerance, or glucose-induced insulin secretion before treatment or at 3 wk, 6 mo, or 1 yr during treatment. Longer therapeutic trials with larger patient groups will be necessary to decide whether cyclosporin can be safely given for many years without risk of developing diabetes mellitus.
Robertson
R P
RP
Department of Medicine, University of Minnesota, Minneapolis 55455.
Franklin
G
G
Nelson
L
L
D001786:Blood Glucose / Q000032:analysis*; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000627:therapeutic use*; D004311:Double-Blind Method; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000097:blood*; D007515:Islets of Langerhans / Q000503:physiopathology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D011897:Random Allocation
D001786:Blood Glucose; D003524:Cyclosporins; D007328:Insulin